Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Arch Pathol Lab Med ; 136(2): 163-71, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22288963

ABSTRACT

CONTEXT: Differentiation of non-small cell carcinoma into histologic types is important because of new, successful therapies that target lung adenocarcinoma (ACA). TTF-1 is a favored marker for lung ACA but has limited sensitivity and specificity. Napsin A (Nap-A) is a functional aspartic proteinase that may be an alternative marker for primary lung ACA. OBJECTIVES: To compare Nap-A versus TTF-1 in the typing of primary lung carcinoma and the differentiation of primary lung ACA from carcinomas of other sites. DESIGN: Immunohistochemistry for Nap-A and TTF-1 was performed on tissue microarrays of 1674 cases of carcinoma: 303 primary lung ACAs (18.1%), 200 primary squamous cell lung carcinomas (11.9%), 52 primary small cell carcinomas of the lung (3.1%), and carcinomas of the kidney (n  =  320; 19.1%), thyroid (n  =  96; 5.7%), biliary (n  =  89; 5.3%), bladder (n  =  47; 2.8%), breast (n  =  93; 5.6%), colon (n  =  95; 5.7%), liver (n  =  96; 5.7%), ovaries (n  =  45; 2.7%), pancreas (n  =  48; 2.9%), prostate (n  =  49; 2.9%), stomach (n  =  93; 5.6%), and uterus (n  =  48; 2.9%). Cases were evaluated against a negative control as negative, weak positive, and strong positive. RESULTS: Nap-A was more sensitive than TTF-1 for primary lung ACA (87% versus 64%; P < .001). Nap-A was more specific than TTF-1 for primary lung ACA versus all tumors, excluding kidney, independent of tumor type (P < .001). CONCLUSIONS: Nap-A is superior to TTF-1 in distinguishing primary lung ACA from other carcinomas (except kidney), particularly primary lung small cell carcinoma, and primary thyroid carcinoma. A combination of Nap-A and TTF-1 is useful in the distinction of primary lung ACA (Nap-A(+), TTF-1(+)) from primary lung squamous cell carcinoma (Nap-A(-), TTF-1(-)) and primary lung small cell carcinoma (Nap-A(-), TTF-1(+)).


Subject(s)
Adenocarcinoma/diagnosis , Aspartic Acid Endopeptidases/metabolism , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Small Cell/diagnosis , Lung Neoplasms/diagnosis , Nuclear Proteins/metabolism , Transcription Factors/metabolism , Adenocarcinoma/metabolism , Adult , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Small Cell/metabolism , Diagnosis, Differential , Humans , Lung/metabolism , Lung/pathology , Lung Neoplasms/metabolism , Sensitivity and Specificity , Thyroid Nuclear Factor 1
2.
Rev Esp Cardiol ; 62(4): 365-72, 2009 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-19401121

ABSTRACT

INTRODUCTION AND OBJECTIVES: To investigate the role of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 (PAI-1) gene in patients with ST-elevation myocardial infarction (STEMI) aged < or =45 years and its influence on regulation of the plasma PAI-1 concentration. METHODS: This case-control study included 127 consecutive patients aged < or =45 years with a diagnosis of STEMI who were admitted to a cardiovascular intensive care unit and 127 controls recruited between January 2006 and March 2007. Participants were genotyped for the 4G/5G polymorphism using the polymerase chain reaction and restriction fragment length polymorphism analysis, and their plasma PAI-1 concentrations were measured. Informed consent was obtained from all participants. RESULTS: There was a significant difference in genotype distribution between the two groups (P< .002). The 4G allele occurred more frequently in the patient group (P=.032). In addition, there were significant independent associations between STEMI and the 4G allele (i.e., 4G/4G plus 4G/5G; odds ratio [OR]=2.29; 95% confidence interval [CI], 1.12-4.68; P=.022), smoking (OR=23.23; 95% CI, 8.92-60.47; P< .001), a family history of cardiovascular disease (OR=4.66; 95% CI, 2.06-10.52; P=.001) and hypertension (OR=5.42; 95% CI, 1.67-17.56; P=.005). The plasma PAI-1 concentration was higher in individuals who were homozygous for the 4G allele (P< .001). CONCLUSIONS: The study findings indicate that the 4G allele is an independent risk factor for acute myocardial infarction in young patients, as are smoking, hypertension and a family history of inherited cardiovascular disease.


Subject(s)
Myocardial Infarction/epidemiology , Myocardial Infarction/genetics , Plasminogen Activator Inhibitor 1/genetics , Acute Disease , Adult , Electrocardiography , Female , Gene Frequency , Genotype , Humans , Male , Mexico/epidemiology , Middle Aged , Myocardial Infarction/physiopathology , Odds Ratio , Polymorphism, Genetic , Risk Factors
3.
Rev. esp. cardiol. (Ed. impr.) ; 62(4): 365-372, abr. 2009. tab, graf
Article in Spanish | IBECS | ID: ibc-72640

ABSTRACT

Introducción y objetivos. Determinar la participación del polimorfismo 4G/5G en el gen del inhibidor del activador del plasminógeno tipo 1 (PAI-1) en pacientes con infarto agudo de miocardio con elevación del segmento ST y edad ≤ 45 años y su influencia en la regulación de la concentración plasmática de PAI-1. Métodos. En un estudio de casos y controles se incluyó, entre enero de 2006 y marzo de 2007, a 127 pacientes consecutivos con diagnóstico de infarto agudo de miocardio con elevación del segmento ST ingresados a la unidad de cuidados intensivos cardiovasculares y 127 controles. Se realizó genotipificación del polimorfismo 4G/5G mediante técnica de reacción en cadena de la polimerasa-polimorfismos en la longitud del fragmento de restricción, y la determinación de la concentración plasmática de PAI-1. Todos los pacientes firmaron consentimiento informado. Resultados. Se identificó una diferencia con significación estadística en la distribución genotípica entre los grupos (p < 0,002). La frecuencia del alelo 4G fue mayor en el grupo de estudio (p = 0,032). Se asociaron en forma independiente al infarto agudo de miocardio con elevación del segmento ST el alelo 4G (4G/4G + 4G/5G) (odds ratio [OR] = 2,29; intervalo de confianza [IC] del 95%, 1,12-4,68; p = 0,022), el tabaquismo (OR = 23,23; IC del 95%, 8,92-60,47; p < 0,001), el antecedente familiar de enfermedad cardiovascular (OR = 4,66; IC del 95%, 2,06-10,52; p < 0,001) y la hipertensión arterial (OR = 5,42; IC del 95%, 1,67-17,56; p = 0,005). Las concentraciones plasmáticas de PAI-1 fueron mayores en los homocigotos 4G (p < 0,001). Conclusiones. Estos resultados indican que el alelo 4G es un factor independiente de riesgo de infarto agudo de miocardio en pacientes jóvenes, al igual que el tabaquismo, la hipertensión arterial y los antecedentes hereditarios familiares de enfermedad cardiovascular (AU)


Introduction and objectives. To investigate the role of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 (PAI-1) gene in patients with ST elevation myocardial infarction (STEMI) aged ≤45 years and its influence on regulation of the plasma PAI-1 concentration. Methods. This case-control study included 127 consecutive patients aged ≤45 years with a diagnosis of STEMI who were admitted to a cardiovascular intensive care unit and 127 controls recruited between January 2006 and March 2007. Participants were genotyped for the 4G/5G polymorphism using the polymerase chain reaction and restriction fragment length polymorphism analysis, and their plasma PAI-1 concentrations were measured. Informed consent was obtained from all participants. Results. There was a significant difference in genotype distribution between the 2 groups (P < .002). The 4G allele occurred more frequently in the patient group (P=.032). In addition, there were significant independent associations between STEMI and the 4G allele (ie, 4G/4G plus 4G/5G; odds ratio [OR] =2.29; 95% confidence interval [CI], 1.12-4.68; P=.022), smoking (OR=23.23; 95% CI, 8.92-60.47; P < .001), a family history of cardiovascular disease (OR=4.66; 95% CI, 2.06-10.52; P=.001) and hypertension (OR=5.42; 95% CI, 1.67-17.56; P=.005). The plasma PAI-1 concentration was higher in individuals who were homozygous for the 4G allele (P < .001). Conclusions. The study findings indicate that the 4G allele is an independent risk factor for acute myocardial infarction in young patients, as are smoking, hypertension, and a family history of inherited cardiovascular disease (AU)


Subject(s)
Humans , Male , Female , Adult , Polymorphism, Genetic/physiology , Plasminogen/administration & dosage , Plasminogen Activators/therapeutic use , Myocardial Infarction/genetics , Fibrinolysis/genetics , Fibrinolysis/physiology , Thrombosis/complications , Thrombosis/physiopathology , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/immunology , Case-Control Studies , Myocardial Infarction/complications , Informed Consent/standards , Diabetes Mellitus/epidemiology , Polymorphism, Genetic , Diabetes Mellitus/therapy , Hypertension/complications , Hyperlipidemias/complications , Hyperlipidemias/therapy
4.
Am J Physiol Cell Physiol ; 295(1): C257-67, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18495808

ABSTRACT

In two-dimensional (2-D) culture systems, we have previously shown that cleaved two-chain high-molecular-weight kininogen (HKa) or its domain 5 induced apoptosis by disrupting urokinase plasminogen activator (uPA) receptor (uPAR)-integrin signal complex formation. In the present study, we used a three-dimensional (3-D) collagen-fibrinogen culture system to monitor the effects of HKa on tube formation. In a 3-D system, HKa significantly inhibited tube and vacuole formation as low as 10 nM, which represents 1.5% of the physiological concentration of high-molecular-weigh kininogen (660 nM), without apparent apoptosis. However, HKa (300 nM) completely inhibited tube formation and increased apoptotic cells about 2-fold by 20-24 h of incubation. uPA-dependent ERK activation and uPAR internalization regulate cell survival and migration. In a 2-D system, we found that exogenous uPA-induced ERK phosphorylation and uPAR internalization were blocked by HKa. In a 3-D system, we found that not only uPA-uPAR association but also the activation of ERK were inhibited by HKa. HKa disrupts the uPA-uPAR complex, inhibiting the signaling pathways, and also inhibits uPAR internalization and regeneration to the cell surface, thereby interfering with uPAR-mediated cell migration, proliferation, and survival. Thus, our data suggest that the suppression of ERK activation and uPAR internalization by HKa contributes to the inhibition of tube formation. We conclude that in this 3-D collagen-fibrinogen gel, HKa modulates the multiple functions of uPAR in endothelial cell tube formation, a process that is closely related to in vivo angiogenesis.


Subject(s)
Endothelial Cells/physiology , Kininogens/physiology , Receptors, Cell Surface/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Apoptosis , Cell Adhesion , Cell Movement , Cells, Cultured , Endothelial Cells/drug effects , Endothelium, Vascular/cytology , Extracellular Signal-Regulated MAP Kinases/physiology , Humans , Kininogens/pharmacology , Phosphorylation , Receptors, Urokinase Plasminogen Activator , Signal Transduction
5.
Exp Cell Res ; 314(4): 774-88, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-18062965

ABSTRACT

Cleaved high molecular weight kininogen (HKa), as well as its domain 5 (D5), inhibits migration and proliferation induced by angiogenic factors and induces apoptosis in vitro. To study its effect on tube formation we utilized a collagen-fibrinogen, three-dimensional gel, an in vitro model of angiogenesis. HKa, GST-D5 and D5 had a similar inhibitory effect of tube length by 90+/-4.5%, 86+/-5.5% and 77+/-12.9%, respectively. D5-derived synthetic peptides: G440-H455 H475-H485 and G486-K502 inhibited tube length by 51+/-3.7%, 54+/-3.8% and 77+/-1.7%, respectively. By a comparison of its inhibitory potency and its sequences, a functional sequence of HKa was defined to G486-G496. PP2, a Src family kinase inhibitor, prevented tube formation in a dose-dependent manner (100-400 nM), but PP3 at 5 microM, an inactive analogue of PP2, did not. HKa and D5 inhibited Src 416 phosphorylation by 62+/-12.3% and 83+/-6.1%, respectively. The C-terminal Src kinase (Csk) inhibits Src kinase activity. Using a siRNA to Csk, expression of Csk was down-regulated by 86+/-7.0%, which significantly increased tube length by 27+/-5.8%. The addition of HKa and D5 completely blocked this effect. We further showed that HKa inhibited Src family kinase activity by disrupting the complex of uPAR, alphavbeta3 integrin and Src. Our results indicate that the anti-angiogenic effect of HKa and D5 is mediated at least in part through Src family kinases and identify a potential novel target for therapeutic inhibition of neovascularization in cancer and inflammatory arthritis.


Subject(s)
Endothelium, Vascular/cytology , Kininogen, High-Molecular-Weight/pharmacology , Neovascularization, Physiologic , src-Family Kinases/metabolism , Cell Adhesion , Cells, Cultured , Collagen/chemistry , Down-Regulation , Endothelium, Vascular/drug effects , Extracellular Matrix/chemistry , Fibrinogen/chemistry , Gels , Humans , Kininogen, High-Molecular-Weight/chemistry , Peptides/pharmacology , Protein Structure, Tertiary
7.
Arterioscler Thromb Vasc Biol ; 27(9): 1968-75, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17585065

ABSTRACT

OBJECTIVE: The cleaved form of high molecular weight kininogen (HKa) is a potent inhibitor of angiogenesis and tumor growth in vivo; the functional domain has been identified as domain 5 (D5, named as kininostatin). We now identify the subcellular targeting site for D5 on endothelial cells (ECs), and investigate D5 inhibition of integrin functions. METHODS AND RESULTS: Endothelial membrane rafts were isolated using sucrose density gradient centrifugation. D5, bound to ECs, was predominantly associated with membrane rafts, in which uPAR, a HKa receptor, was also localized. In contrast, other HKa receptors, cytokeratin-1 and gC1q receptor, were not detected in membrane rafts. Colocalization of D5 with caveolin-1 was demonstrated on ECs by confocal microscopy. Disruption of membrane rafts by cholesterol removal decreased D5 binding to ECs. On stimulation with vascular endothelial growth factor, alpha(v)beta3 integrin formed a complex with uPAR and caveolin-1, which was accompanied by an increase in ligand binding affinity of alpha(v)beta3 integrin. These events were inhibited by D5. Consistently, D5 suppressed specific alpha(v)beta3 integrin-mediated EC adhesion and spreading as well as small guanosine triphosphatase Rac1 activation. CONCLUSIONS: D5 binds to ECs via membrane rafts and downregulates alpha(v)beta3 integrin bidirectional signaling and the downstream Rac1 activation pathway.


Subject(s)
Cell Adhesion/physiology , Endothelial Cells/physiology , Integrin alphaVbeta3/metabolism , Kininogen, High-Molecular-Weight/physiology , Angiogenesis Inhibitors/physiology , Cell Membrane/metabolism , Down-Regulation , Humans , Umbilical Veins/physiology
8.
Am J Physiol Heart Circ Physiol ; 292(6): H2959-65, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17293494

ABSTRACT

High-molecular-weight kininogen (HK) and its domain 3 (D3) exhibit anticoagulant properties and inhibit platelet activation at low thrombin concentration in vitro. We hypothesized that the rapid occlusive thrombosis in HK-deficient (HKd) rats following endothelial injury of the aorta results from enhanced platelet aggregation by thrombin. The effects of D3 (G235-M357) or D3-derived peptides on thrombosis in vivo were tested. D3 and its exon 7C terminal peptide (E7CP, K270-Q292), expressed as glutathione S-transferase (GST) fusion proteins (GST-D3, GST-E7CP), or GST alone, as well as cleaved HK (HKa) or synthetic peptide E7CP, were infused intravenously 10 min before endothelial injury. Blood flow was reduced down to 10% of baseline flow within 28 +/- 5.2 min by a platelet-fibrin thrombus in GST-treated HKd rats compared with >240 min in GST-treated normal HK rats (wild type). GST-D3, GST-E7CP, HKa, or E7CP infusion prolonged the flow time to 233, >240, 223, and >240 min, respectively, in HKd rats. When GST-E7CP was infused 10 min after the injury, blood flow was maintained for >240 min. Thrombin-antithrombin concentrations were elevated by injury in HKd rats receiving GST from 35 to 55 microg/l and decreased with GST-E7CP, HKa, or E7CP reconstitution to 40, 15, and 9 microg/l, respectively. We conclude that HKd rats are prothrombotic and that HKa, kininogen D3, and its fragment E7CP modulate arterial thrombosis after endothelial injury.


Subject(s)
Aorta/metabolism , Endothelium, Vascular/metabolism , Fibrinolytic Agents/metabolism , Kininogen, High-Molecular-Weight/metabolism , Peptide Fragments/metabolism , Thrombosis/metabolism , Amino Acid Sequence , Animals , Animals, Genetically Modified , Antithrombin III , Aorta/drug effects , Aorta/injuries , Aorta/pathology , Aorta/physiopathology , Blood Flow Velocity , Disease Models, Animal , Endothelium, Vascular/drug effects , Endothelium, Vascular/injuries , Endothelium, Vascular/pathology , Endothelium, Vascular/physiopathology , Fibrin/metabolism , Fibrinolytic Agents/chemistry , Fibrinolytic Agents/pharmacology , Fibrinolytic Agents/therapeutic use , Glutathione Transferase/genetics , Kininogen, High-Molecular-Weight/chemistry , Kininogen, High-Molecular-Weight/genetics , Kininogen, High-Molecular-Weight/pharmacology , Kininogen, High-Molecular-Weight/therapeutic use , Male , Molecular Sequence Data , Peptide Fragments/genetics , Peptide Fragments/pharmacology , Peptide Hydrolases/blood , Platelet Aggregation , Protein Structure, Tertiary , Rats , Rats, Inbred Lew/genetics , Recombinant Fusion Proteins/metabolism , Regional Blood Flow , Thrombin/metabolism , Thrombosis/pathology , Thrombosis/physiopathology , Thrombosis/prevention & control
9.
J Cell Physiol ; 211(2): 504-12, 2007 May.
Article in English | MEDLINE | ID: mdl-17219411

ABSTRACT

OBJECTIVE: To evaluate the effect of a thrombospondin 1 (TSP1)-derived peptide on inflammation and angiogenesis in an animal model of erosive arthritis and to assess the relationship between TSP1 and connective tissue growth factor (CTGF) in the pathophysiology of rheumatoid arthritis. METHODS: Erosive arthritis in Lewis rats was induced by peptidoglycan-polysaccharide (PG-PS). Animals were divided into four groups: (1) negative control and groups receiving, (2) no treatment, (3) treatment with a TSP1-derived peptide, and (4) treatment with a scrambled peptide. Samples obtained from ankle joint, spleen and liver were studied using histology, histomorphometry, immunohistochemistry and RT-PCR. RESULTS: Histological data indicated that the TSP1-derived peptide treatment decreased neovascularization, leukocyte infiltration and thickening of the synovial lining of the joint, and reduced granuloma formation in the spleen and liver when compared to control groups. Higher concentrations of CTGF and TSP1 proteins were observed in the affected areas of animals which did not receive TSP1-derived peptide treatment. Also, immunofluorescence and RT-PCR analyses showed an increase in CTGF protein expression and regulation, respectively, in the tissues of untreated animals when compared to the TSP1-derived peptide treated animals. By immunofluorescence, TSP1 expression was decreased in the TSP1-derived peptide treated animals. Moreover, macrophage/monocyte-specific staining revealed a decrease in cell infiltration in the articular tissue of the TSP1-derived peptide treated animals. CONCLUSION: Both inflammation and angiogenesis were decreased after TSP1-derived peptide treatment indicating a potential pathway by which TSP1 interaction with neutrophils induces CTGF in RA affected tissues.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antirheumatic Agents/pharmacology , Arthritis, Experimental/drug therapy , Immediate-Early Proteins/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Neovascularization, Pathologic/drug therapy , Peptides/pharmacology , Thrombospondin 1/pharmacology , Animals , Ankle Joint/drug effects , Ankle Joint/pathology , Anti-Inflammatory Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Experimental/chemically induced , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Cartilage, Articular/drug effects , Cartilage, Articular/pathology , Connective Tissue Growth Factor , Female , Gene Expression/drug effects , Granuloma/drug therapy , Granuloma/metabolism , Hepatomegaly/drug therapy , Hepatomegaly/metabolism , Immediate-Early Proteins/genetics , Immunohistochemistry , Inflammation/drug therapy , Inflammation/metabolism , Intercellular Signaling Peptides and Proteins/genetics , Leukocytes/drug effects , Leukocytes/pathology , Macrophages/drug effects , Macrophages/pathology , Neovascularization, Pathologic/chemically induced , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Peptides/therapeutic use , Peptidoglycan , Polysaccharides , RNA, Messenger/metabolism , Rats , Rats, Inbred Lew , Reverse Transcriptase Polymerase Chain Reaction , Splenomegaly/drug therapy , Splenomegaly/metabolism , Thrombospondin 1/metabolism , Thrombospondin 1/therapeutic use , Time Factors
10.
Cancer Immunol Immunother ; 55(7): 797-807, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16187087

ABSTRACT

Multiple myeloma (MM), a B-cell malignancy characterized by proliferation of monoclonal plasma cells remains incurable. Murine plasma cell tumors share common features with human MM. We used two cell lines (B38 and C11C1) derived from P3X63Ag8 myeloma cells. The new cell lines were implanted subcutaneously in the strain of origin (Balb/c mice) and used as a model to monitor the effects of C11C1 monoclonal antibody (mAb) to kininogen (HK). We assessed their behavior by intraperitoneal and subcutaneous implantation, by implanting them together and by treating B38-MM with purified mAb C11C1. We evaluated growth, microvascular density (MVD), and cellular expression of urokinase-type plasminogen activator-receptor (uPAR), fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), bradykinin-1 receptor (B1R), bradykinin-2 receptor (B2R) and HK. We found that both MM-cell-lines are uPAR positive, that mAb C11C1 inhibits its own tumor growth in vivo, slows down B38-MM growth rate when both MM are implanted together and when mAb C11C1 is injected intraperitoneally. MAb C11C1-treated-MM showed decreased MVD and HK binding in vivo without FGF-2, B1R or B2R expression changes. We propose that the B38-extramedullary-myeloma-model is a useful tool to study the interactions of this hematopoietic tumor and its environment and that mAb C11C1 may improve the efficacy of conventional MM treatment with minimal side effects.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Kininogens/immunology , Multiple Myeloma/therapy , Neovascularization, Pathologic/therapy , Animals , Antibody Specificity , Cell Line, Tumor/pathology , Cell Line, Tumor/transplantation , Fibroblast Growth Factor 2/biosynthesis , Fibroblast Growth Factor 2/genetics , Gene Expression Regulation, Neoplastic/drug effects , Mice , Mice, Inbred BALB C , Microcirculation/drug effects , Multiple Myeloma/blood supply , Multiple Myeloma/pathology , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Neovascularization, Pathologic/physiopathology , Receptor, Bradykinin B1/biosynthesis , Receptor, Bradykinin B1/genetics , Receptor, Bradykinin B2/biosynthesis , Receptor, Bradykinin B2/genetics , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/genetics , Receptors, Urokinase Plasminogen Activator , Subcutaneous Tissue , Vascular Endothelial Growth Factor A/biosynthesis , Vascular Endothelial Growth Factor A/genetics
11.
Rev. invest. clín ; 57(6): 802-813, Nov.-Dec. 2005. ilus
Article in Spanish | LILACS | ID: lil-632401

ABSTRACT

The plasma kallikrein-kinin system (KKS) participates in the pathogenesis of inflammatory reactions involved in cellular injury, coagulation, fibrinolysis, kinin formation, complement activation, cytokine secretion and release of proteases. It has been shown that KKS activation in the systemic inflammatory response syndrome results in decrease of its component plasma proteins. Similar changes have been documented in diabetes, sepsis, children with vasculitis, allograft rejection, disseminated intravascular coagulation, patients with recurrent pregnancy losses, hereditary angioedema, adult respiratory distress syndrome and coronary artery disease. Direct involvement of the KKS in the pathogenesis of experimental acute arthritis and acute and chronic enterocolitis has been documented by previous studies from our laboratory using experimental animal models. It has been found that in HK deficient Lewis rats, experimental IBD was much less severe. We showed a genetic difference in kininogen structure between resistant Buffalo and susceptible Lewis rats, which results in accelerated cleavage of HK and it is responsible for the susceptibility to the inflammatory process in the Lewis rats. It has been demostrated that therapy with a specific plasma kallikrein inhibitor (P8720) modulated the experimental enterocolitis, arthritis and systemic inflammation. Furthermore, it has been shown that a bradykinin 2 receptor (B2R) antagonist attenuates the inflammatory changes in the same animal model. We have showed that a monoclonal antibody targeting HK decreases angiogénesis and arrests tumor growth in a syngeneic animal model. In summary, these results indicate that the plasma KKS plays a central role in the pathogenesis of chronic intestinal inflammation, arthritis and angiogenesis.


Se ha demostrado la participación del sistema plasmático de kalikreína-kininas (KKS) en el proceso inflamatorio, el cual incluye reacciones de daño celular, coagulación y fibrinólisis, formación de kininas, activación del complemento, secreción de citoquinas y liberación de proteasas. El KKS se encuentra activado en el síndrome de respuesta inflamatoria sistémica con una disminución en la concentración plasmática de las proteínas que lo constituyen. También se ha demostrado una activación similar en la diabetes, choque séptico, vasculitis en infantes, enfermedad injerto-huésped, coagulación intravascular diseminada, pacientes con abortos de repetición, angioedema hereditario, el síndrome de estrés respiratorio del adulto y enfermedad coronaria arterial. Mediante el uso de modelos animales experimentales, nuestro laboratorio ha demostrado una participación directa del KKS en la patogénesis de la artritis experimental aguda y la enterocolitis aguda y crónica. Se ha demostrado que en la rata tipo Lewis, cuando es deficiente de kininógeno de alto peso molecular (HK), la enfermedad inflamatoria intestinal es menos severa comparada con la presentada en ratas con niveles normales de HK como la Buffalo. Nosotros mostramos una diferencia entre el gene que codifica la molécula del kininógeno de la rata tipo Buffalo (resistentes) y Lewis (susceptibles), que resulta en un incremento de la actividad proteolítica de kalikreína sobre su substrato HK, lo cual predispone a las ratas Lewis al desarrollo de la enfermedad inflamatoria crónica. Se ha demostrado una disminución en las manifestaciones inflamatorias sistémicas de la enterocolitis y artritis experimental mediante el uso de un inhibidor específico de la kalikreína (P8720). Además, el antagonista del receptor 2 de la bradikinina (BR2) atenuó los cambios inflamatorios en el mismo modelo animal. Asimismo, se ha demostrado que las ratas Lewis deficientes de kininógeno desarrollaron inflamación intestinal sistémica menos severa. Mediante el uso del anticuerpo monoclonal C11C1 contra HK se logró una disminución de la angiogenesis y, consecuentemente, el crecimiento tumoral. En conclusión, los resultados demuestran que el sistema plasmático de KKS desempeña un papel preponderante en la patogénesis de la artritis reumatoide, la enfermedad intestinal crónica y en el proceso angiogénico.


Subject(s)
Animals , Rats , Kallikrein-Kinin System/physiology , Kininogen, High-Molecular-Weight/physiology , Neovascularization, Physiologic/physiology , Amino Acid Sequence , Antibodies, Monoclonal/immunology , Arthritis, Reactive/physiopathology , Boron Compounds/therapeutic use , Cell Adhesion/physiology , Fibrinolysis/physiology , Genetic Predisposition to Disease , Inflammation/physiopathology , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/physiopathology , Kininogen, High-Molecular-Weight/biosynthesis , Kininogen, High-Molecular-Weight/chemistry , Kininogen, High-Molecular-Weight/deficiency , Kininogen, High-Molecular-Weight/genetics , Kininogen, High-Molecular-Weight/therapeutic use , Models, Molecular , Molecular Sequence Data , Oligopeptides/therapeutic use , Peptidoglycan/toxicity , Polysaccharides, Bacterial/toxicity , Rats, Inbred BUF , Rats, Inbred Lew , Structure-Activity Relationship
12.
Arthritis Rheum ; 52(8): 2549-52, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16059911

ABSTRACT

OBJECTIVE: To compare inflammatory peripheral arthritis in wild-type and high molecular weight kininogen (HK)-deficient rats, both on the genetically susceptible Lewis background. METHODS: By backcrossing Brown-Norway HK-deficient rats with Lewis rats for 6 generations, 2 new strains were produced, wild-type F6 and HK-deficient F6, each with a 98.5% Lewis genome. Inflammatory arthritis was induced by intraperitoneal injection of peptidoglycan-polysaccharide (PG-PS), and the clinical, histopathologic, and biochemical responses were compared in both strains. RESULTS: Eighteen days after PG-PS injection, rats with normal concentrations of HK showed weight loss and marked increase in hind ankle diameter with severe synovial inflammation and cartilage abnormalities. In contrast, HK-deficient rats showed no weight loss (P < 0.05), no increase in hind ankle diameter (P < 0.05), and an absence of inflammatory changes (P < 0.05), as measured by the histologic and morphometric Mankin grading system for synovial and cartilage injury. CONCLUSION: Plasma HK is a key mediator of acute and chronic inflammatory arthritis in genetically susceptible Lewis rats.


Subject(s)
Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Kininogen, High-Molecular-Weight/deficiency , Animals , Arthritis, Experimental/blood , Arthritis, Experimental/chemically induced , Body Weight , Drug Combinations , Foot/pathology , Hindlimb , Injections, Intraperitoneal , Joints/pathology , Kallikrein-Kinin System , Peptidoglycan/administration & dosage , Polysaccharides/administration & dosage , Rats , Rats, Inbred BN , Rats, Inbred Lew
13.
Arthritis Res Ther ; 7(4): R769-76, 2005.
Article in English | MEDLINE | ID: mdl-15987478

ABSTRACT

The human leukocyte antigen B27 (HLA-B27) transgenic rat is a model of human inflammatory bowel disease, rheumatoid arthritis and psoriasis. Studies of chronic inflammation in other rat models have demonstrated activation of the kallikrein-kinin system as well as modulation by a plasma kallikrein inhibitor initiated before the onset of clinicopathologic changes or a deficiency in high-molecular-mass kininogen. Here we study the effects of monoclonal antibody C11C1, an antibody against high-molecular-mass kininogen that inhibits the binding of high-molecular-mass kininogen to leukocytes and endothelial cells in the HLA-B27 rat, which was administered after the onset of the inflammatory changes. Thrice-weekly intraperitoneal injections of monoclonal antibody C11C1 or isotype IgG1 were given to male 23-week-old rats for 16 days. Stool character as a measure of intestinal inflammation, and the rear limbs for clinical signs of arthritis (tarsal joint swelling and erythema) were scored daily. The animals were killed and the histology sections were assigned a numerical score for colonic inflammation, synovitis, and cartilage damage. Administration of monoclonal C11C1 rapidly decreased the clinical scores of pre-existing inflammatory bowel disease (P < 0.005) and arthritis (P < 0.001). Histological analyses confirmed significant reductions in colonic lesions (P = 0.004) and synovitis (P = 0.009). Decreased concentrations of plasma prekallikrein and high-molecular-mass kininogen were found, providing evidence of activation of the kallikrein-kinin system. The levels of these biomarkers were reversed by monoclonal antibody C11C1, which may have therapeutic potential in human inflammatory bowel disease and arthritis.


Subject(s)
Antibodies, Monoclonal/therapeutic use , HLA-B27 Antigen/biosynthesis , Inflammation/metabolism , Kininogens/biosynthesis , Animals , Animals, Genetically Modified , Antibodies, Monoclonal/pharmacology , Arthritis/drug therapy , Arthritis/genetics , Arthritis/metabolism , Colitis/drug therapy , Colitis/genetics , Colitis/metabolism , HLA-B27 Antigen/genetics , Humans , Inflammation/drug therapy , Inflammation/genetics , Kininogens/genetics , Male , Rats , Rats, Inbred F344
14.
Arch Med Res ; 36(1): 87-95, 2005.
Article in English | MEDLINE | ID: mdl-15900628

ABSTRACT

Inflammation is accompanied by activation of the plasma kallikrein-kinin system (KKS). KKS activation has been demonstrated in a variety of inflammatory human diseases. To further explore the participation of KKS in arthritis and inflammatory bowel disease, we used two experimental animal models in arthritis and enterocolitis. We found that activation of KKS is associated with arthritis induced by intraperitoneal injection of peptidoglycan-polysaccharide polymers (PG-PS) as well as the enterocolitis and systemic inflammation induced also by PG-PS when injected into the intestinal wall of genetically susceptible Lewis rats. We postulated that KKS participates in the pathogenesis of inflammatory reactions involved in cellular injury, coagulation, fibrinolysis, kinin formation, complement activation, cytokine secretion, and release of proteases. We demonstrated that therapy with a specific plasma kallikrein inhibitor modulated the experimental enterocolitis, arthritis, and systemic inflammation. The fact that deficiency of plasma high molecular weight kininogen in the genetically susceptible Lewis rat results in decreased chronic enterocolitis and systemic inflammation also supports our hypothesis. We suggest that KKS plays a similar role in idiopathic human intestinal inflammatory disease and arthritis, making kallikrein-kinin system proteins appealing targets for drug therapy in chronic inflammatory diseases such as rheumatoid arthritis and Crohn's disease.


Subject(s)
Inflammation/blood , Intestines , Kallikrein-Kinin System/immunology , Kininogens/blood , Kininogens/chemistry , Amino Acid Sequence , Animals , Arthritis, Experimental/metabolism , Humans , Intestines/immunology , Intestines/pathology , Kininogens/genetics , Molecular Sequence Data , Molecular Weight , Protein Structure, Secondary
15.
Rev Invest Clin ; 57(6): 802-13, 2005.
Article in Spanish | MEDLINE | ID: mdl-16708906

ABSTRACT

The plasma kallikrein-kinin system (KKS) participates in the pathogenesis of inflammatory reactions involved in cellular injury, coagulation, fibrinolysis, kinin formation, complement activation, cytokine secretion and release of proteases. It has been shown that KKS activation in the systemic inflammatory response syndrome results in decrease of its component plasma proteins. Similar changes have been documented in diabetes, sepsis, children with vasculitis, allograft rejection, disseminated intravascular coagulation, patients with recurrent pregnancy losses, hereditary angioedema, adult respiratory distress syndrome and coronary artery disease. Direct involvement of the KKS in the pathogenesis of experimental acute arthritis and acute and chronic enterocolitis has been documented by previous studies from our laboratory using experimental animal models. It has been found that in HK deficient Lewis rats, experimental IBD was much less severe. We showed a genetic difference in kininogen structure between resistant Buffalo and susceptible Lewis rats, which results in accelerated cleavage of HK and it is responsible for the susceptibility to the inflammatory process in the Lewis rats. It has been demostrated that therapy with a specific plasma kallikrein inhibitor (P8720) modulated the experimental enterocolitis, arthritis and systemic inflammation. Furthermore, it has been shown that a bradykinin 2 receptor (B2R) antagonist attenuates the inflammatory changes in the same animal model. We have showed that a monoclonal antibody targeting HK decreases angiogenesis and arrests tumor growth in a syngeneic animal model. In summary, these results indicate that the plasma KKS plays a central role in the pathogenesis of chronic intestinal inflammation, arthritis and angiogenesis.


Subject(s)
Kallikrein-Kinin System/physiology , Kininogen, High-Molecular-Weight/physiology , Neovascularization, Physiologic/physiology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Arthritis, Reactive/physiopathology , Boron Compounds/therapeutic use , Cell Adhesion/physiology , Fibrinolysis/physiology , Genetic Predisposition to Disease , Inflammation/physiopathology , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/physiopathology , Kininogen, High-Molecular-Weight/biosynthesis , Kininogen, High-Molecular-Weight/chemistry , Kininogen, High-Molecular-Weight/deficiency , Kininogen, High-Molecular-Weight/genetics , Kininogen, High-Molecular-Weight/therapeutic use , Models, Molecular , Molecular Sequence Data , Oligopeptides/therapeutic use , Peptidoglycan/toxicity , Polysaccharides, Bacterial/toxicity , Rats , Rats, Inbred BUF , Rats, Inbred Lew , Structure-Activity Relationship
16.
Arch Med Res ; 35(5): 369-77, 2004.
Article in English | MEDLINE | ID: mdl-15610905

ABSTRACT

Inflammation is accompanied by activation of the plasma kallikrein-kinin system (KKS). KKS activation has been demonstrated in a variety of inflammatory human diseases. To further explore the participation of KKS in arthritis and inflammatory bowel disease, we used two experimental animal models in arthritis and enterocolitis. We found that activation of KKS is associated with arthritis induced by intraperitoneal injection of peptidoglycan-polysaccharide polymers (PG-PS) as well as the enterocolitis and systemic inflammation induced also by PG-PS when injected into the intestinal wall of genetically susceptible Lewis rats. We postulated that KKS participates in the pathogenesis of inflammatory reactions involved in cellular injury, coagulation, fibrinolysis, kinin formation, complement activation, cytokine secretion, and release of proteases. We demonstrated that therapy with a specific plasma kallikrein inhibitor modulated the experimental enterocolitis, arthritis, and systemic inflammation. The fact that deficiency of plasma high molecular weight kininogen in the genetically susceptible Lewis rat results in decreased chronic enterocolitis and systemic inflammation also supports our hypothesis. We suggest that KKS plays a similar role in idiopathic human intestinal inflammatory disease and arthritis, making kallikrein-kinin system proteins appealing targets for drug therapy in chronic inflammatory diseases such as rheumatoid arthritis and Crohn's disease.


Subject(s)
Arthritis, Experimental , Enterocolitis , Kininogen, High-Molecular-Weight , Amino Acid Sequence , Animals , Arthritis, Experimental/blood , Arthritis, Experimental/immunology , Enterocolitis/blood , Enterocolitis/immunology , Humans , Kininogen, High-Molecular-Weight/blood , Kininogen, High-Molecular-Weight/immunology , Molecular Sequence Data , Protein Conformation , Rats , Rats, Inbred Lew
17.
Am J Pathol ; 165(3): 969-76, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15331420

ABSTRACT

We reported that high-molecular weight kininogen is proangiogenic by releasing bradykinin and that a monoclonal antibody to high-molecular weight kininogen, C11C1, blocked its binding to endothelial cells. We now test if this antibody can prevent arthritis and systemic inflammation in a Lewis rat model. We studied 32 animals for 16 days. Group I (negative control) received saline intraperitoneally. Group II (disease-treated) received peptidoglycan-polysaccharide simultaneously with C11C1. Group III (disease-untreated) received peptidoglycan-polysaccharide simultaneously with isotype-matched mouse IgG. Group IV (disease-free-treated) and group V (disease-free isotype-treated) received saline and C11C1 or mouse IgG. Analysis of joint diameter changes showed a decrease in the C11C1 disease-treated group compared to the disease-untreated group. The hind paw inflammatory score showed a decrease in the intensity and extent of inflammation between the disease-untreated and the C11C1 disease-treated group. Prekallikrein, high-molecular weight kininogen, factor XI, and factor XII were decreased in the disease-untreated group compared to the C11C1 disease-treated group. T-kininogen was increased in the disease-untreated group when compared with the C11C1 disease-treated group. Disease-free groups IV and V did not show any sign of inflammation at any time. This study shows that monoclonal antibody C11C1 attenuates plasma kallikrein-kinin system activation, local and systemic inflammation, indicating therapeutic potential in reactive arthritis.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Arthritis, Reactive/prevention & control , Disease Models, Animal , Kininogen, High-Molecular-Weight/immunology , Angiogenesis Inhibitors/therapeutic use , Animals , Arthritis, Reactive/blood , Arthritis, Reactive/chemically induced , Factor XI/metabolism , Factor XII/metabolism , Female , Humans , Neovascularization, Physiologic/immunology , Peptidoglycan , Rats , Rats, Inbred Lew
18.
Blood ; 104(7): 2065-72, 2004 Oct 01.
Article in English | MEDLINE | ID: mdl-15161672

ABSTRACT

We have shown that human high molecular weight kininogen is proangiogenic due to release of bradykinin. We now determined the ability of a murine monoclonal antibody to the light chain of high molecular weight kininogen, C11C1, to inhibit tumor growth compared to isotype-matched murine IgG. Monoclonal antibody C11C1 efficiently blocks binding of high molecular weight kininogen to endothelial cells in a concentration-dependent manner. The antibody significantly inhibited growth of human colon carcinoma cells in a nude mouse xenograft assay and was accompanied by a significant reduction in the mean microvascular density compared to the IgG control group. We also showed that a hybridoma producing monoclonal antibody C11C1 injected intramuscularly exhibited markedly smaller tumor mass in a syngeneic host compared to a hybridoma producing a monoclonal antibody to the high molecular weight kininogen heavy chain or to an unrelated plasma protein. In addition, tumor inhibition by purified monoclonal antibody C11C1 was not due to direct antitumor effect because there was no decrease of tumor cell growth in vitro in contrast to the in vivo inhibition. Our results indicate that monoclonal antibody C11C1 inhibits angiogenesis and human tumor cell growth in vivo and has therapeutic potential for treatment of human cancer.


Subject(s)
Bradykinin/chemistry , Immunotherapy/methods , Kininogen, High-Molecular-Weight/chemistry , Neoplasms/therapy , Neovascularization, Pathologic , Animals , Antibodies, Monoclonal/chemistry , Apoptosis , Cell Division , Cell Line, Tumor , Dose-Response Relationship, Immunologic , Endothelium, Vascular/cytology , Endothelium, Vascular/immunology , Factor XII/metabolism , HEPES/chemistry , Humans , Hybridomas/chemistry , Hybridomas/metabolism , Hybridomas/pathology , Immunoglobulin G/chemistry , Immunohistochemistry , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Transplantation , Protein Structure, Tertiary , Surface Plasmon Resonance , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...